What is Wedbush’s Estimate for ANRO FY2029 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities research analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for shares of Alto Neuroscience in a report issued on Thursday, March 20th. Wedbush analyst L. Chico anticipates that the company will earn ($2.88) per share for the year. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share.

Separately, William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Friday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.75.

Alto Neuroscience Stock Performance

Shares of ANRO opened at $2.71 on Monday. Alto Neuroscience has a 12-month low of $2.58 and a 12-month high of $18.35. The business has a 50-day simple moving average of $3.63 and a two-hundred day simple moving average of $6.05. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09.

Institutional Investors Weigh In On Alto Neuroscience

Large investors have recently added to or reduced their stakes in the business. AWM Investment Company Inc. boosted its holdings in Alto Neuroscience by 22.9% in the fourth quarter. AWM Investment Company Inc. now owns 687,831 shares of the company’s stock worth $2,910,000 after acquiring an additional 128,100 shares in the last quarter. Woodline Partners LP boosted its holdings in Alto Neuroscience by 397.6% in the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company’s stock worth $2,631,000 after acquiring an additional 496,976 shares in the last quarter. Vestal Point Capital LP boosted its holdings in Alto Neuroscience by 40.8% in the fourth quarter. Vestal Point Capital LP now owns 915,000 shares of the company’s stock worth $3,870,000 after acquiring an additional 265,000 shares in the last quarter. Two Sigma Investments LP boosted its holdings in Alto Neuroscience by 137.2% in the fourth quarter. Two Sigma Investments LP now owns 30,700 shares of the company’s stock worth $130,000 after acquiring an additional 17,760 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Alto Neuroscience by 73.1% in the fourth quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company’s stock valued at $7,158,000 after purchasing an additional 714,461 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.